PacBio (PACB) announces its critical role in a study to be published in Nature Genetics. The study, titled Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition, showcases how researchers leveraged PacBio’s advanced sequencing solutions, including the synchronized Fiber-seq and Kinnex multiomic approach, to uncover the genetic and molecular basis of a rare and complex Mendelian condition.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Largest borrow rate increases among liquid names
- PacBio announces GIFS at USask as first Revio PacBio CSP in Canada
- PacBio, Radboud UMC announces study results using HiFi long read sequencing
- PacBio reports Q4 preliminary revenue $39.2M, consensus $40.63M
- PacBio, Intus Bio collaborate for launch of GutID